Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is well-positioned for success in the biopharmaceutical industry as they have a clear differentiating factor in their drug ZUNVEYL, which has shown lower incidence of GI-related side effects and insomnia, as well as potential impact on behavioral symptoms of Alzheimer's disease. The company also has a potential market expansion opportunity with their sublingual ODT formulation and a strong financial position with a recent settlement agreement and new director appointment. Furthermore, they have reported strong revenue and a net loss beat for the first quarter, with a positive outlook for future revenue growth and sufficient cash on hand to fund operations until cash flow break-even.

Bears say

Alpha Cognition is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's. Despite the company's current efforts to commercialize and market its lead product ZUNVEYL, there are several concerns that could impact its success, including slow market uptake, pricing pressures, and potential setbacks in clinical trials. Overall, the company faces significant risks and may struggle to achieve profitability in the near term.

ACOG has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACOG has a Strong Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.